Über das Unternehmen
- Firmenname (rechtlich): Hybio Pharmaceutical Co.,Ltd
- Registrierungsland: China
- Adresse: Hybio Innovation Industry Building, , No. 7, Guansheng 4th Rd, , Guanlan High-tech Park,, Shenzhen
- Anzahl der Mitarbeiter: 500 - 999
Beschreibung:
Founded in 1998, Hybio is a high-tech enterprise specializing in R&D and manufacturing of diverse peptide products, growing into a leading peptide pharmaceutical company and the first of its kind to go public in China (2011, stock code 300199). The company offers a full range of peptide products (API and finished dosage forms) and services (CRO and CDMO), with peptide finished products mainly sold domestically and peptide APIs supplied worldwide, and its Shenzhen headquarters has passed local and national NMPA GMP inspections more than 90 times.
Geschäftsaktivitäten
Pharmazeutische Wirkstoffe (API)
HerstellerAPI-Hersteller
Fertigarzneiformen
HerstellerAPI-Hersteller
Original-Wirkstoffe
HerstellerAPI-Hersteller
Absatzmärkte
- East Asia: China, Democratic People's Republic of Korea, Mongolia, Republic of Korea, Japan, Taiwan
- South Asia: Bangladesh, Bhutan, India, Maldives, Nepal, Pakistan, Sri Lanka, Afghanistan, Iran
- Mainland Southeast Asia: Cambodia, Lao People's Democratic Republic, Myanmar, Thailand, Viet Nam, Brunei Darussalam, Indonesia, Malaysia, Philippines, Timor-Leste, Singapore
- Melanesia: Papua New Guinea
- Western Asia: United Arab Emirates, Armenia, Azerbaijan
Hauptprodukte/-dienstleistungen
Unsere Produkte & Dienstleistungen
Sell · Active Pharmaceutical Ingredients (APIs)
Sell · Active Pharmaceutical Ingredients (APIs)
Certifications
FDA
GMP
Proofs
CPHI Americas 2026
06/2026 – 06/2026
CPHI Americas 2026
Bewertungen
(0)
(0)
(0)
(0)
(0)
Kommentare
Filter:
Sortieren nach:
Keine Kommentare verfügbar.
Bewertung & Kommentar hinterlassen